BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17160925)

  • 1. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological complications in Fabry disease.
    Dütsch M; Hilz MJ
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S243-50. PubMed ID: 21211673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
    García de Lorenzo A;
    Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurological complications of Anderson-Fabry disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
    Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological aspects of Fabry disease].
    Clavelou P; Besson G
    Presse Med; 2007 Mar; 36 Spec No 1():1S65-8. PubMed ID: 17546771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
    Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
    J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Changing Landscape of Fabry Disease.
    Svarstad E; Marti HP
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fabry disease in 2004].
    Germain DP
    Rev Prat; 2003 Dec; 53(20):2215-20. PubMed ID: 15018073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
    Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
    G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
    Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
    Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.